Dostarlimab-Gxly

Neoadjuvant immunotherapy alone resulted in significant treatment response among most patients with mismatch-repair-deficient early-stage solid tumors, according to study results.

September is Gynecologic Cancer Awareness Month.

The FDA expanded the approval of dostarlimab-gxly for treatment of endometrial cancer.

CHICAGO — A phase 2 study evaluating dostarlimab in adults with mismatch repair-deficient locally advanced rectal cancer has maintained a 100% clinical complete response rate at a median follow-up of almost 18 months.

A regimen containing dostarlimab plus standard-of-care chemotherapy significantly improved OS compared with chemotherapy alone in women with primary advanced or recurrent endometrial cancer, according to the agent’s manufacturer.

The FDA approved dostarlimab in combination with chemotherapy for certain women with endometrial cancer.

CHICAGO — Assessment of RUBY trial outcomes by blinded independent central review confirmed the benefits of adding dostarlimab to chemotherapy for women with primary advanced or recurrent endometrial cancer.

Dostarlimab plus carboplatin significantly increased PFS among women with primary advanced or recurrent endometrial cancer, according to study results presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Data from a pair of single-arm clinical trials will be sufficient to illustrate the benefits and risks of dostarlimab-gxly for a subgroup of patients with rectal cancer, according to the FDA’s Oncologic Drugs Advisory Committee.

The FDA granted regular approval to dostarlimab-gxly for treatment of certain women with endometrial cancer.